Astria Therapeutics Inc. Overview
Astria Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, operates within the Health Care sector, specifically in the Biotechnology industry. The company is publicly traded on the Nasdaq with its financials reported in USD.
Recent Financial Performance
As of June 11, 2025, Astria Therapeutics closed at a price of $5.6 per share. The company’s stock has experienced significant volatility over the past year, reaching a 52-week high of $12.92 on September 19, 2024, and a 52-week low of $3.555 on April 8, 2025. The market capitalization of Astria Therapeutics stands at approximately $294.59 million.
Company Focus and Strategy
Astria Therapeutics is dedicated to the discovery, development, and commercialization of therapeutic treatments for rare diseases. Additionally, the company is actively working on product candidates aimed at addressing serious lipid disorders. This dual focus underscores the company’s commitment to addressing unmet medical needs in both rare and more common health conditions.
Conclusion
Astria Therapeutics continues to navigate the biopharmaceutical landscape with a strategic emphasis on rare diseases and lipid disorders. Despite recent stock price fluctuations, the company maintains a significant market presence, driven by its innovative approach to drug development.